Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA.
Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, P. Vall d'Hebron 119-129, Barcelona 08035, Spain.
Immunol Allergy Clin North Am. 2022 Aug;42(3):657-669. doi: 10.1016/j.iac.2022.05.002.
The best therapeutic approach to patients with asthma-chronic obstructive pulmonary disease overlap (ACO) is unknown. Current treatment recommendations rely on expert opinions, roundtable discussions, and strategy documents, because patients with ACO have been excluded from most clinical studies in asthma and COPD. Because of the underlying asthma initial therapy, early use of inhaled corticosteroids along with a long-acting bronchodilator is recommended. If maintenance inhaler therapy is not effective, advanced therapies based on phenotyping and identification of treatable traits may be considered.
对于哮喘-慢性阻塞性肺疾病重叠（ACO）患者，最佳的治疗方法尚不清楚。目前的治疗建议依赖于专家意见、圆桌讨论和策略文件，因为 ACO 患者已被排除在大多数哮喘和 COPD 的临床研究之外。由于潜在的哮喘初始治疗，建议早期使用吸入皮质激素加长效支气管扩张剂。如果维持吸入治疗无效，可以考虑基于表型和可治疗特征识别的高级治疗方法。
